Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors

Alpelisib is a selective inhibitor of PI3Kα, shown to improve outcomes for PIK3CA mutant, hormone receptor positive (HR+) metastatic breast cancers (MBC) when combined with antiestrogen therapy. To uncover mechanisms of resistance, we conducted a detailed, longitudinal analysis of tumor and plasma c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Cancer
Main Authors: Razavi, Pedram, Dickler, Maura N., Shah, Payal D., Toy, Weiyi, Brown, David N., Won, Helen H., Li, Bob T., Shen, Ronglai, Vasan, Neil, Modi, Shanu, Jhaveri, Komal, Caravella, Betty Ann, Patil, Sujata, Selenica, Pier, Zamora, Stephen, Cowan, Aimee M., Comen, Elizabeth, Singh, Andy, Covey, Anne, Berger, Michael F., Hudis, Clifford A., Norton, Larry, Nagy, Rebecca J., Odegaard, Justin I., Lanman, Richard B., Solit, David B., Robson, Mark E., Lacouture, Mario E., Brogi, Edi, Reis-Filho, Jorge S., Moynahan, Mary Ellen, Scaltriti, Maurizio, Chandarlapaty, Sarat
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7450824/
https://ncbi.nlm.nih.gov/pubmed/32864625
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s43018-020-0047-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados